Patents by Inventor Ian M. Mawer

Ian M. Mawer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolone derivatives as dopamine D.sub.4 ligands
    Patent number: 5607946
    Abstract: A class of chemical compounds comprising a 2(1H)-quinolone moiety and a substituted heterocyclic moiety, linked via the 3-position of the 2(1H)-quinolone moiety by a methylene group, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: August 30, 1995
    Date of Patent: March 4, 1997
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
  • Indole derivatives as dopamine D.sub.4 antagonists
    Patent number: 5576336
    Abstract: Compounds of formula (I), or a salt or prodrug thereof, wherein R represent hydrogen or C.sub.1-6 alkyl; Q represents a moiety of formula Qa or Qb; they are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: November 19, 1996
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Raymond Baker, Howard B. Broughton, Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
  • Hydroxyquinolone derivatives
    Patent number: 5559125
    Abstract: A class of 4-hydroxy-2-(1H)-quinolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: September 24, 1996
    Assignee: Merck, Sharp & Dohme Limited
    Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer, Michael Rowley
  • Tetramic acid derivatives
    Patent number: 5420155
    Abstract: A class of 4-hydroxy-2(1H)-pyrrolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 30, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Janusz J. Kulagowski, Paul D. Leeson, Ian M. Mawer
  • Hydroxyquinolone derivatives compounds which have pharmaceutical utility
    Patent number: 5348962
    Abstract: This present invention relates to a class of 4-hydroxy-2-(1H)-quinolones which are substituted in the 3-position by an optionally substituted aryl substituent. These compounds are selective non-competitive antagonists of N-methyl-D-aspartate (NMDA) receptors.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: September 20, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Janusz J. Kulagowski, Ian M. Mawer, Paul D. Leeson, Michael Rowley